Background: Fibromyalgia syndrome (FMS), is one of the most common causes of widespread pain and diffuse tenderness.
INTRODUCTION
Fibromyalgia syndrome (FMS) is a chronic disease with an unknown etiology, which is characterized by widespread pain in the musculoskeletal system, tender points, sleeping disorders, and chronic fatigue. Familial component, environmental factors, endocrinological factors neurotransmitter changes and psychological factors are suggested to contribute in the development of FMS 1 . Most patients with fibromyalgic syndrome (FMS) complain of sleep disturbances, fatigue and pain. These symptoms might be a consequence of changed melatonin (MT) secretion, since MT is known to have sleep promoting properties.
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It has been reported that patients with this syndrome have a higher serum concentration of serotonin autoantibodies not only when compared with healthy controls 10 , but also when compared with patients with other rheumatic diseases 11 . Also low serum levels of both serotonin 22, 26 and its precursor tryptophan 20 appear to prevail in patients with FMS.
Melatonin (MT) is a very popular neurohormone frequently investigated in recent years. MT was suggested to be effective in the etiology and treatment of some diseases. MT is synthesized primarily in the pineal gland in the brain 21 .
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PATIENTS AND METHODS
This is a case control cross sectional observational study that included fifty FM patients, all were fulfilling the American Colleague of Rheumatology (ACR) criteria for FMS 24 . They were selected from the inpatient and/or the out patients' clinics of the Rheumatology and Immunology department at Benha teaching Hospital. Twenty apparently healthy subjects of comparable age and sex were included as a control group.
All patients underwent full history taking and clinical examination including assessment of FM disease activity using the 2010 ACR FMS criteria 24 .
A patient satisfies the diagnostic criteria for fibromyalgia if the following 3conditions are met: An antibody specific to MT was bound to micro wells. Samples are then added to the micro wells with a biotin-conjugated antibody specific for Melatonin (MT) and avidin conjugated to Horseradish Peroxidase (HRP) is added to each micro wells and incubated. Then a TMB (3,3´,5,5´tetramethyl-benzidine) substrate solution is added to each well. Only those wells that contain MT, biotin-conjugated antibody and enzyme-conjugated avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wave lenght of 450 nm ± 2 nm. The concentration of melatonin is then determined in the samples.
Statistical Analysis
Statistical analysis of the results were carried out using SPSS software statistical computer package version 14.0(SPSS Inc., IL). Statistical differences between groups were determined by student's unpaired t-test. Significance was taken to be p≤0.05. Correlation coefficient (r) was used for measuring the relationship between two variables.
RESULTS
Demographic data, clinical and laboratory features of FMS patients:
This study included 50 FMS patients; all are females (100%) and no males (0%), their age ranged between 17-60 years (30.5±9.8 years), disease duration (5.6±1.6 years) and MT level varying from 10-120 pg/ml (32.5±13.9). 
DISCUSSION
Fibromyalgia is a common rheumatologic disorder that is under diagnosed. Using the 1990 ACR classification criteria, the prevalence of fibromyalgia in the general population is reported to be higher than in women than in men 19 . There is a higher prevalence in females because females produce more neurotransmitters that increase pain signals and fewer neurotransmitters that decrease pain signals than males, so in our study we observe that all FM patients are females 15 . Studies suggested that when endogenous tryptop han is depleted, there is a dramatic drop in synthesis of serotonin in females 17 . This make females being more sensitive to depression and pain (FMS) 26 . The FM syndrome may coexist with other rheumatic diseases such as rheumatoid arthritis and systemic lupus erthymatosus in this case fibromyalgia is considered a secondary type 2 . Disturbances in melatonin secretion have been proposed to be part of the pathophysiology of FMS.
The circadian rhythm 12 of melatonin secretion have been examined in patients with FMS 13 , Non significant differences were observed in the 24-hr plasma melatonin level 12 . We found that MT level was lower in primary FMS patients compared with healthy age and sex-matched subjects. The clinical implication of this finding is disturbed sleep at night and, as consequence, daytime sleepiness, fatigue and increased pain perception. Sleep disturbances, fatigue and cognitive dysfunction, are the hall mark of FMS, present in almost all patients with FMS 8, 16 , including those in this study. In our study, MT levels of FMS patients were found to be significantly lower than in control group. There was positive correlation between the MT levels and pain, fatigue, and sleeping disorders. Our results weren't agree with the study of Press et al., Senel et al. & Klerman 12, 18, 20 . In agreement with our results Wikner et al. 22 have investigated eight patients with FM and eight controls, the concentration of melatonin in plasma and urine was found to be significantly lower in patients with FM However, Korszun et al. 13 however, reported that the melatonin concentration in urine was elevated in patients with FM when compared to controls.
Our data imposed that, in 1ry FMS there were significant negative correlations of MT titers with each of tender points (r=-0,967**, p<0.0001), sleep disturbance (r=-0.963**, p<0.0001**), fatigue (r=-0.972**, p<0.001**), WPI (r=-0,933**, p<0..0001) and SS (r=-0.934**, p<0.0001).
While, there were positive correlations of MT titers with Cognitive symptoms (r=0.36, p<0.061).
Some authors had reported that patients with depression have decreased secretion of MT and increased secretion of cortisol 3 . As most FMS patients show signs of depression, a decreased MT level may explain most of their symptoms. Decreased MT synthesis may be brought about by impaired provision of tryptophan. The amino acid tryptophan transforms to serotonin in the pineal gland, which then transforms into MT hormone. The decrease in serotonin as a result of the decrease in the absorption of tryptophan in FMS patients was suggested to be responsible for the decrease in MT synthesis, and accordingly that this may result in the abnormal sleeping pattern and typical FMS pain 9 . For patients with rheumatoid arthritis (RA), social disadvantage, psychological distress and RA severity predicted future development of FMS 3 . Many studies 5 confirmed that melatonin levels are increased in rheumatoid arthritis patients compared with sex and age matched healthy controls. Melatonin has been reported to stimulate the production of IL6 and Th1 related proinflammatory cytokines such as IL12, IL1&IL2, which are involved in the pathophysiology of rheumatoid arthritis 6 . Melatonin is also synthesized in human bone marrow cells 4 . However, it has been found to be present at a rather high concentration in synovial fluid in rheumatoid patients, and recently it has been reported that synovial macrophages from rheumatoid patients have specific binding sites for melatonin 14 . Interestingly, the levels of plasma melatonin were highest in SLE patients. Plasma melatonin levels did not correlate with measures of clinical disease activity in SLE 7 . In the current study melatonin level was found to be higher in 2ry FMS patients, who are having RA/ SLE compared with healthy age and sex-matched volunteer subjects. This agrees with the studies that observed that MT levels are higher in RA/SLE patients with secondary fibromyalgias 5 . Also in this study there is a significant correlation between MT level and clinical features of 2ry FMS such as sleep disturbance, fatigue & others.
Our results regarding 2ry FMS; there were a statistically significant negative correlations between MT titers with each of tender points (r=-0,880**, p<0.0001), sleep disturbance (r=-0.859**, p<0.0001**), fatigue (r=-0.167**, p<0.001**), WPI (r=-0,812**, p<0.0001) and SS (r=-0.799**, p<0.0001).
While, there were significant positive correlations of MT titers with cognitive symptoms (r=0.04, p<0.848).
Melatonin level didn ' t seem to play a role in secondary fibromyalgia which may be induced by other factors which should be investigated in the future.
Conclusion
Our study indicated that FMS associated with sleep disturbance, fatigue & cognitive dysfunction. Low MT level in primary fibromyalgia patients & high MT level in secondary fibromyalgia patients was observed. There was a negative correlations between
